These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

263 related articles for article (PubMed ID: 19602211)

  • 41. Therapeutic efficacy of pooled buffy-coat platelet components prepared and stored with a platelet additive solution.
    van Rhenen DJ; Gulliksson H; Cazenave JP; Pamphilon D; Davis K; Flament J; Corash L
    Transfus Med; 2004 Aug; 14(4):289-95. PubMed ID: 15285725
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Comparison of blood component preparation methods from whole blood bags based on buffy coat extraction.
    Cid J; Claparols M; Pinacho A; Hernández JM; Ortiz P; Puig LS; Pla RP
    Transfus Apher Sci; 2007 Jun; 36(3):243-7. PubMed ID: 17569593
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Effect of bedside filtration on aggregates from cold-stored whole blood-derived platelet-rich plasma and apheresis platelet concentrates.
    Li VJ; Bailey SL; Miles J; Usaneerungrueng C; Fang LY; Corson J; Osborne B; Özpolat T; López JA; Wu Y; Stolla M
    Transfusion; 2022 Jan; 62(1):22-27. PubMed ID: 34778992
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Preparation of platelet concentrates.
    Greening DW; Sparrow RL; Simpson RJ
    Methods Mol Biol; 2011; 728():267-78. PubMed ID: 21468955
    [TBL] [Abstract][Full Text] [Related]  

  • 45. A scalable, micropore, platelet rich plasma separation device.
    Dickson MN; Amar L; Hill M; Schwartz J; Leonard EF
    Biomed Microdevices; 2012 Dec; 14(6):1095-102. PubMed ID: 22811077
    [TBL] [Abstract][Full Text] [Related]  

  • 46. The combined effect of platelet storage media and intercept pathogen reduction technology on platelet activation/activability and cellular apoptosis/necrosis: Lisbon-RBS experience.
    Carvalho H; Alguero C; Santos M; de Sousa G; Trindade H; Seghatchian J
    Transfus Apher Sci; 2006 Apr; 34(2):187-92. PubMed ID: 16574488
    [TBL] [Abstract][Full Text] [Related]  

  • 47. How to optimize the preparation of leukocyte- and platelet-rich fibrin (L-PRF, Choukroun's technique) clots and membranes: introducing the PRF Box.
    Dohan Ehrenfest DM
    Oral Surg Oral Med Oral Pathol Oral Radiol Endod; 2010 Sep; 110(3):275-8; author reply 278-80. PubMed ID: 20727495
    [No Abstract]   [Full Text] [Related]  

  • 48. Preparation of leukocyte-poor platelet concentrates via a short, hard spin of a pool of buffy coats.
    van Delden CJ; Faber RD; de Wit HJ; Smit Sibinga CT
    Vox Sang; 2000; 78(3):164-70. PubMed ID: 10838517
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Extended storage of platelets in SSP platelet additive solution.
    Hornsey VS; McColl K; Drummond O; McMillan L; Morrison A; Morrison L; MacGregor IR; Prowse CV
    Vox Sang; 2006 Jul; 91(1):41-6. PubMed ID: 16756600
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Preparation of Platelet Concentrates for Research and Transfusion Purposes.
    Greening DW; Simpson RJ; Sparrow RL
    Methods Mol Biol; 2017; 1619():31-42. PubMed ID: 28674875
    [TBL] [Abstract][Full Text] [Related]  

  • 51. International forum: Europe. Buffy-coat-derived platelet concentrates: Swedish experience.
    Högman CF; Berséus O; Eriksson L; Gulliksson H
    Transfus Sci; 1997 Mar; 18(1):3-13. PubMed ID: 10174288
    [TBL] [Abstract][Full Text] [Related]  

  • 52. The influence of various hematology analyzers on component platelet counts.
    Moroff G; Sowemimo-Coker SO; Finch S; Murphy S; Brandwein H; Whitbread J; Wenz B
    Transfus Med Rev; 2005 Apr; 19(2):155-66. PubMed ID: 15852243
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Effects of plasma nitric oxide levels on platelet activation in single donor apheresis and random donor concentrates.
    Büyükkağnici DI; Ilhan O; Kavas GO; Arslan O; Arat M; Dalva K; Ayyildiz E
    Transfus Apher Sci; 2007 Feb; 36(1):73-8. PubMed ID: 17236811
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Evaluation of platelet parameters in healthy apheresis donors using the ADVIA 120.
    Ifran A; Haşimi A; Kaptan K; Nevruz O; Beyan C; Erbil K
    Transfus Apher Sci; 2005 Oct; 33(2):87-90. PubMed ID: 16139569
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Therapeutic Effect of Apheresis and Buffy Coat-Derived Platelet Concentrates.
    Zimmermann R
    Clin Lab; 2024 Aug; 70(8):. PubMed ID: 39193973
    [No Abstract]   [Full Text] [Related]  

  • 56. Cold storage of pooled, buffy-coat-derived, leucoreduced platelets in plasma.
    Hornsey VS; Drummond O; McMillan L; Morrison A; Morrison L; MacGregor IR; Prowse CV
    Vox Sang; 2008 Jul; 95(1):26-32. PubMed ID: 18393944
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Evaluation of factors that can modify platelet-rich plasma properties.
    Andrade MG; de Freitas Brandão CJ; Sá CN; de Bittencourt TC; Sadigursky M
    Oral Surg Oral Med Oral Pathol Oral Radiol Endod; 2008 Jan; 105(1):e5-e12. PubMed ID: 18155603
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Preparation of blood products for transfusion: is there a best method?
    Devine DV; Serrano K
    Biologicals; 2012 May; 40(3):187-90. PubMed ID: 22119012
    [TBL] [Abstract][Full Text] [Related]  

  • 59. L-carnitine improves pH and decreases surface phosphatidylserine expression in extended stored apheresis platelets.
    Sweeney JD; Kouttab NM; Arduini A
    J Clin Apher; 2004; 19(2):98-102. PubMed ID: 15274203
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Platelet activation during storage of platelet concentrates processed from buffy coats by the automated OrbiSac system.
    Larrea González L; Oritiz de Salazar MI; Roig R; Soler MA
    Transfusion; 2007 Aug; 47(8):1555-6; author reply 1556. PubMed ID: 17655605
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.